Sunvozertinib

Buy Sunvozertinib (Zegfrovy) Tablets in India
Generic Name/API:Sunvozertinib
Packaging:Each bottle contains 30 tablets of the same strength (150 mg or 200 mg).
Storage:Store at 20°C to 25°C (68°F to 77°F)
Dosage:The recommended dose is 200 mg orally once daily taken with food.
Strength:It is available in 150 mg and 200 mg tablets.
Indication:Zegfrovy is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Zegfrovy (Sunvozertinib) is a kinase inhibitor used in the following cases:

  • Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. 

Strength: 

It is available in 150 mg and 200 mg tablets.

Dosage: 

The recommended dose is 200 mg orally once daily taken with food. 

Adverse Effects:

  • Diarrhea
  • Rash
  • Decreased appetite
  • Stomatitis
  • Fatigue
  • Nausea
  • Paronychia
  • Vomiting
  • Constipation
  • Musculoskeletal pain
  • Pruritus
  • Dry skin
  • Urinary tract infection
  • Abdominal pain 
  • Decreased weight. 

Storage:

Store the tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) 

  • Interstitial Lung Disease/Pneumonitis:

Patients taking Zegfrovy can cause severe and life-threatening interstitial lung disease (ILD)/pneumonitis. Monitor patients for new or worsening pulmonary symptoms such as dyspnea, cough, and fever that indicate ILD/Pneumonitis.  Immediately withhold Zegfrovy in patients with suspected ILD/pneumonitis and permanently discontinue Zegfrovy if ILD/pneumonitis is confirmed 

  • Gastrointestinal Adverse Reactions: 

Some of the gastrointestinal symptoms such as diarrhoea, nausea and vomiting can occur due to Zegfrovy. Administer this medication with food to reduce gastrointestinal adverse reactions. Monitor patients for gastrointestinal toxicity, and provide supportive care, including anti-diarrheals, anti-emetics, or fluid replacement, as indicated. Withhold, reduce the dose, or permanently discontinue Zegfrovy based on severity.

  • Dermatologic Adverse Reactions:

Rash, acneiform dermatitis and pruritus may occur with the use of Zegfrovy. Instruct patients to use alcohol-free (e.g., isopropanol-free, ethanol-free) emollient cream during treatment with Zegfrovy and to avoid the use of irritating skin products (e.g., products containing retinol or retinoic acid, benzoyl peroxides). Withhold, reduce the dose, or permanently discontinue Zegfrovy based on severity.

  • Ocular Toxicity:

The ocular symptoms of patients taking Zegfrovy therapy include keratitis, dry eye symptoms, blurred vision, and visual impairment. Promptly refer patients with new or worsening eye symptoms to an ophthalmologist. Advise discontinuation of contact lenses until ocular symptoms are evaluated. Withhold, reduce the dose, or permanently discontinue Zegfrovy based on severity.

Process to Import Medicine

FAQ

It is recommended for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

The recommended dose of Sunvozertinib (Zegfrovy) is 200 mg taken orally once daily with food, as directed by the treating healthcare professional.

If a dose of medication is missed within 12 hours, take the dose. If a dose of the medication is missed by more than 12 hours, skip the missed dose and take the next dose at the regularly scheduled time.

Yes, Sunvozertinib (Zegfrovy) can cause ocular toxicity including keratitis, dry eye symptoms, blurred vision, and visual impairment. Consult an ophthalmologist in case of new or worsening symptoms. Advise discontinuation of contact lenses until ocular symptoms are evaluated.

Zegfrovy (Sunvozertinib) may cause fetal harm and is not recommended during pregnancy. Consult your healthcare professional before use.

The cost of Zegfrovy (Sunvozertinib) tablets in India may vary as the medicine may not be readily available locally and may require international sourcing. Currency fluctuations and import duties can influence the final price. For the latest pricing information, contact 247QualityMeds at +91 9967979080.

To buy Sunvozertinib (Zegfrovy) tablets in Delhi, submit an enquiry along with a valid prescription. Our team can assist with the applicable process for accessing the medicine.

You can buy Zegfrovy (Sunvozertinib) tablets online in India by contacting 247QualityMeds with a valid prescription. Our team can help you with the ordering and medicine access process.

Related products